Dendritic Cell Based Therapy of Metastatic Breast Cancer

Inclusion Criteria: * Histologically proven progressive metastatic or locally advanced breast cancer * No standard treatment indicated * Age: \> 18 * WHO-Performance Status 0-1 * At least tone measurable tumor lesions according to the RECIST criteria. * Expression of the HLA-A2 tissue type * Life expectancy more than 3 months * Acceptable CBC and blood chemistry results * Written informed consent Exclusion Criteria: * Patients with a history of any other neoplastic disease less than 5 years ago (excepting treated carcinomas in situ of the cervix and basal/squamous cell carcinomas of the skin). * Patients with metastatic disease in the central nervous system (CNS). * Patients with other significant illness including severe allergy, asthma, angina pectoris or congestive heart failure. * Patients with acute or chronic infection including HIV, hepatitis and tuberculosis. * Patients who are pregnant. * Patients who have received antineoplastic therapy including chemotherapy or immunotherapy less than 4 weeks before beginning the trial. * Patients who receive corticosteroids or other immunosuppressive agents. * Patients with active autoimmune diseases such as lupus erythematosus, rheumatoid arthritis or thyroiditis.